RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday

RAPT Therapeutics (NASDAQ:RAPT) is projected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect RAPT Therapeutics to post earnings of ($0.45) per share for the quarter.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $1.17 on Thursday. The company’s 50 day simple moving average is $1.30 and its 200 day simple moving average is $1.61. The stock has a market capitalization of $40.90 million, a price-to-earnings ratio of -0.42 and a beta of 0.03. RAPT Therapeutics has a 1 year low of $0.79 and a 1 year high of $10.05.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RAPT shares. Wells Fargo & Company reduced their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, December 26th. Stifel Nicolaus restated a “hold” rating and set a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Finally, Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.